Trial Profile
A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, International Phase III Study With a 28-week Extension Period to Evaluate the Safety and Efficacy of Dapagliflozin 10mg Once Daily in Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and Sulfonylurea.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 09 Jun 2015 Results of post-hoc analysis presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 09 Jun 2015 Results of post-hoc analysis presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 17 Jun 2014 Results of the 52-week study was presented at the 74th Annual Scientific Sessions of the American Diabetes Association.